Summary
An age-stratified subgroup analysis of the SQUIRE trial demonstrated that patients aged < 70 years exhibited significant survival benefits when necitumumab was added to gemcitabine/cisplatin chemotherapy as first-line treatment for stage IV squamous non–small cell lung cancer. This survival advantage was not observed in the elderly ≥ 70-year subgroup.
- squamous non–small cell lung cancer
- stage IV
- elderly population
- SQUIRE study
- necitumumab
- gemcitabine/cisplatin
- first-line treatment
- overall survival
- progression-free survival
- oncology clinical trials
- © 2015 SAGE Publications
Tools
Age-Stratified Subgroup Analysis of SQUIRE in Patients With Stage IV Squamous NSCLC
Permalink:
Table of contents
Cited By...
- No citing articles found.